West Pharmaceutical Services, Inc. $WST Stock Position Reduced by Handelsbanken Fonder AB

Posted by Geri Gentry on Aug 13th, 2026

Handelsbanken Fonder AB trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 14.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 49,193 shares of the medical instruments supplier’s stock after selling 8,535 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.07% of West Pharmaceutical Services worth $17,660,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in WST. Elyxium Wealth LLC bought a new stake in shares of West Pharmaceutical Services in the 4th quarter worth approximately $25,000. CYBER HORNET ETFs LLC bought a new position in shares of West Pharmaceutical Services during the second quarter worth about $25,000. Cornerstone Planning Group LLC grew its position in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the last quarter. Bayban acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter worth about $27,000. Finally, Private Trust Co. NA increased its holdings in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares during the period. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Stock Up 0.2%

WST stock opened at $352.04 on Thursday. The firm’s 50-day moving average is $345.18 and its two-hundred day moving average is $294.61. The company has a market capitalization of $24.78 billion, a price-to-earnings ratio of 45.08, a price-to-earnings-growth ratio of 2.46 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same quarter last year, the business earned $1.84 earnings per share. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is presently 11.27%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on WST shares. KeyCorp raised their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Citigroup raised their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Buy” and an average target price of $368.08.

Read Our Latest Research Report on WST

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.